← board
TLPH
distress 6/10 · elevated risk$1.28-1%today-12% from 52w high
Revenue
pre-revenue
Liquidity
$21M
Runway
1.9 yrs
Shares 1y
+153%
Price & events
+26.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-5.2%
1W
+21.9%
1M
+60.0%
3M
+28.0%
6M
+190.9%
1Y
+50.6%
2Y
-94.9%
5Y
-94.9%
All
Overview
- Market Cap
- $66.43M
- Volume
- 15.48K
- 52 Week Range
- $0.39 – $1.46
- Total Shares
- 51.90M
- Float Shares
- 26.98M
- Short %
- 1.34%
- % Held by Insiders
- 21.42%
- % Held by Institutions
- 34.76%
- RVOL
- 0.04x
- Beta
- 0.70
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-30WestPark CapitalBuy
- 2025-04-01HC Wainwright & Co.Buy
- 2025-01-21HC Wainwright & Co.Buy
- 2024-08-16HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-08Talphera Inc. (TLPH) Q1 2026 Earnings: EPS Beat Boosts Shares Despite No Revenue - Upward Estimate Revision - dars.gov.et
- 2026-07-08Talphera Inc. (TLPH) Q1 2026 Earnings: EPS Beat Boosts Shares Despite No Revenue - Upward Estimate Revision - dars.gov.et
- 2026-07-08Price to earnings forward of Talphera, Inc. – NASDAQ:TLPH - TradingView
- 2026-06-24TALPHERA (TLPH) director Broadfoot granted RSUs and 30,700 stock options - Stock Titan
- 2026-06-24Talphera shareholders approve director elections and equity plan amendments By Investing.com - Investing.com Nigeria
- 2026-06-24Talphera (TLPH) grants director 5,100 RSUs, 30,700 one-year options - Stock Titan
- 2026-06-24Form 4 Talphera Inc For: 24 June By Investing.com - Investing.com Canada
- 2026-06-24Talphera's Market Cap Up US$6.7m Following Year Of Insider Stock Buying - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.